These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
253 related items for PubMed ID: 1290488
21. Allosteric changes in thrombin's activity produced by peptides corresponding to segments of natural inhibitors and substrates. Hortin GL, Trimpe BL. J Biol Chem; 1991 Apr 15; 266(11):6866-71. PubMed ID: 1849894 [Abstract] [Full Text] [Related]
23. High-resolution NMR studies of fibrinogen-like peptides in solution: interaction of thrombin with residues 1-23 of the A alpha chain of human fibrinogen. Ni F, Konishi Y, Frazier RB, Scheraga HA, Lord ST. Biochemistry; 1989 Apr 04; 28(7):3082-94. PubMed ID: 2742826 [Abstract] [Full Text] [Related]
24. Mechanism of the inhibition of alpha-thrombin by hirudin-derived fragments hirudin(1-47) and hirudin(45-65). Schmitz T, Rothe M, Dodt J. Eur J Biochem; 1991 Jan 01; 195(1):251-6. PubMed ID: 1991472 [Abstract] [Full Text] [Related]
25. Rational design of true hirudin mimetics: synthesis and characterization of multisite-directed alpha-thrombin inhibitors. Lombardi A, Nastri F, Della Morte R, Rossi A, De Rosa A, Staiano N, Pedone C, Pavone V. J Med Chem; 1996 May 10; 39(10):2008-17. PubMed ID: 8642559 [Abstract] [Full Text] [Related]
30. The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin. Vijayalakshmi J, Padmanabhan KP, Mann KG, Tulinsky A. Protein Sci; 1994 Dec 10; 3(12):2254-71. PubMed ID: 7756983 [Abstract] [Full Text] [Related]
31. Allosteric changes of thrombin catalytic site induced by interaction of bothrojaracin with anion-binding exosites I and II. Monteiro RQ, Rapôso JG, Wisner A, Guimarães JA, Bon C, Zingali RB. Biochem Biophys Res Commun; 1999 Sep 07; 262(3):819-22. PubMed ID: 10471408 [Abstract] [Full Text] [Related]
35. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E. Am J Cardiol; 1993 Apr 01; 71(10):778-82. PubMed ID: 8456753 [Abstract] [Full Text] [Related]
36. Pre-clinical and clinical studies on Hirulog: a potent and specific direct thrombin inhibitor. Maraganore JM. Adv Exp Med Biol; 1993 Apr 01; 340():227-36. PubMed ID: 8154339 [No Abstract] [Full Text] [Related]
38. Inhibition by hirulog-1 of generation of plasminogen activator inhibitor-1 from vascular smooth-muscle cells induced by thrombin. Ren S, Fenton JW, Maraganore JM, Angel A, Shen GX. J Cardiovasc Pharmacol; 1997 Mar 01; 29(3):337-42. PubMed ID: 9125671 [Abstract] [Full Text] [Related]
39. Use of fragments of hirudin to investigate thrombin-hirudin interaction. Dennis S, Wallace A, Hofsteenge J, Stone SR. Eur J Biochem; 1990 Feb 22; 188(1):61-6. PubMed ID: 2180697 [Abstract] [Full Text] [Related]
40. A quantitative thrombin time for determining levels of hirudin and Hirulog. Reid TJ, Alving BM. Thromb Haemost; 1993 Oct 18; 70(4):608-16. PubMed ID: 8115987 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]